

AMENDMENTS TO THE CLAIMS

The following listing of claims replaces all prior versions, and listings, of claims in this application.

Listing of Claims

1 - 3. (Cancelled)

4. (Currently amended) A composition according to claim 4 24 wherein the protein crystal diffracts X-rays for a determination of structure coordinates to a resolution greater than 3.0 Angstroms.

5-6. (Canceled)

7. (Currently amended) A method comprising:
forming a crystallization volume comprising a precipitant solution and a protein consisting of SEQ ID NO:1, wherein a protein crystal is formed that has a crystal lattice in a P2₁2₁2₁ space group and unit cell dimensions, +/- 5%, of a=68.7 b=79.6 c=150.2, $\alpha=\beta=\gamma=90^\circ$; and
storing the crystallization volume under conditions suitable for crystal formation of the protein.

8 - 9. (Cancelled)

10. (Previously presented) A method according to claim 7 wherein a protein crystal is formed that diffracts X-rays for a determination of structure coordinates to a resolution greater than 3.0 Angstroms.

11-12. (Canceled)

13. (Previously presented) A method according to claim 7, wherein a protein crystal is formed, the method further comprising diffracting the protein crystal to produce a diffraction pattern and solving the structure of the protein from the diffraction pattern.

14 - 16. (Cancelled)

17. (Withdrawn) The method according to claim 13, the method further comprising:
performing rational drug design using the solved structure; and
identifying an entity that associates with the protein crystal.

18-19. (Cancelled)

20. (Withdrawn) A method according to claim 13, the method further comprising selecting one or more entities based on the rational drug design and contacting the selected entities with the protein.

21. (Withdrawn) A method according to claim 13, the method further comprising measuring an activity of the protein when contacted with the one or more entities.

22. (Withdrawn) A method according to claim 13, the method further comprising comparing activity of the protein in a presence of and in the absence of the one or more entities; and selecting entities where activity of the protein changes depending whether a particular entity is present.

23. (Withdrawn) A method according to claim 13, the method further comprising contacting cells expressing the protein with the one or more entities and detecting a change in a phenotype of the cells when a particular entity is present.

24. (Previously presented) A composition comprising a protein in crystalline form wherein the protein consists of SEQ ID NO:1 and wherein the protein crystal has a crystal lattice in a $P2_12_12_1$ space group and unit cell dimensions, $\pm 5\%$, of $a=68.7$ $b=79.6$ $c=150.2$, $\alpha=\beta=\gamma=90$.